Company Description
enVVeno Medical Corporation, a clinical-stage medical device company, focuses on the development of various bioprosthetic tissue-based solutions to enhance the standard of care in the treatment of venous diseases.
The company’s lead product is the VenoValve, a surgical implant being developed for the treatment of venous Chronic Venous Insufficiency.
Its VenoValve is implanted in the femoral vein and acts as a one-way valve to help restore proper blood flow in the leg; and enVVe, a non-surgical, transcatheter based replacement venous valve for the treatment of CVI.
The company was formerly known as Hancock Jaffe Laboratories, Inc. and changed its name to enVVeno Medical Corporation in October 2021.
enVVeno Medical Corporation was incorporated in 1999 and is based in Irvine, California.
| Country | United States |
| Founded | 1987 |
| Industry | Medical Devices |
| Sector | Healthcare |
| Employees | 31 |
| CEO | Robert Berman |
Contact Details
Address: 70 Doppler Irvine, California 92618 United States | |
| Phone | 949 261 2900 |
| Website | envveno.com |
Stock Details
| Ticker Symbol | NVNO |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001661053 |
| CUSIP Number | 29415J106 |
| ISIN Number | US29415J1060 |
| Employer ID | 33-0936180 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Robert A. Berman | Chief Executive Officer and Director |
| Craig Thomas Glynn | Chief Financial Officer, Treasurer and Secretary |
| Dr. Hamed Alavi Ph.D. | Senior Vice President and Chief Technology Officer |
| Dr. Marc H. Glickman M.D. | Senior Vice President and Chief Medical Officer |
| Warren Hancock | Co-founder |
| Sandy Prietto | Vice President of Marketing |
| Dr. Benedict Broennimann M.D. | Chief Medical Officer of Outside of United States |
| Andrew Cormack | Chief Commercial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 31, 2024 | 10-Q | Quarterly Report |
| Sep 30, 2024 | 8-K | Current Report |
| Sep 30, 2024 | 424B5 | Filing |
| Sep 27, 2024 | FWP | Free Writing Prospectus |
| Sep 26, 2024 | 424B5 | Filing |
| Jul 31, 2024 | 10-Q | Quarterly Report |
| May 10, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
| May 8, 2024 | 10-Q | Quarterly Report |
| Apr 24, 2024 | 8-K | Current Report |
| Mar 6, 2024 | 8-K | Current Report |